15 June 2021 | NewsWebinar video now available: Supporting COVID-19 vaccine access in the Indo-PacificRead the full article
There are broadly four different platforms that are used to develop viral vaccines:
Whole virus and protein vaccines are well-established platforms (refer to Table 1). Examples of whole virus, live attenuated vaccines are measles-mumps-rubella vaccine and rotavirus vaccine; inactivated vaccines: hepatitis A and rabies; and protein vaccines: hepatitis B and acellular pertussis.
Viral vector and nucleic acid vaccines are more novel platforms (refer to Table 2). The only viral vector vaccine licensed for human use is the ebola vaccine by Merck (USA). There is no licensed nucleic acid vaccine.
A description of each platform and general advantages/disadvantages is provided in Tables 1 and 2.
Table 1: Whole virus and protein vaccines
Table 2. Viral vector and nucleic acid vaccines
NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 | Fax (612) 9845 1418 | ABN 53 188 579 090
We acknowledge that the National Centre for Immunisation Research and Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.
Copyright © 2021 NCIRS. All rights reserved
Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.
Stay updated with the latest from NCIRS